Schrodinger, Inc. Annual Report - A Deeper Dive for Investors

Schrodinger, Inc. (NASDAQ: SDGR) stands at the intersection of technology and medicine, using advanced computational methods to revolutionize drug discovery. This summary dives into their latest annual report, the 10-K filing for the fiscal year ended December 31, 2025. As an established company with a consistent reporting history, Schrodinger provides investors with crucial insights into its performance and strategic direction.

Business Overview Schrodinger leads the way in computational drug discovery and materials science. The company develops and licenses a sophisticated software platform that uses physics-based modeling and machine learning to accelerate drug discovery and development. Schrodinger also leverages this powerful platform to advance its own drug candidates, often partnering with pharmaceutical companies.

Financial Performance for Fiscal Year 2025: Schrodinger reported total revenue of $205 million, up 15% year-over-year. This growth primarily stemmed from:

• Software Revenue: Grew 22% to $130 million, reflecting strong demand for its platform and high renewal rates.
• Drug Discovery Revenue: Increased 5% to $75 million, mainly from milestone payments in existing collaborations. Despite this revenue growth, Schrodinger posted a net loss of $85 million for the year, an increase from last year's $70 million loss. This larger loss primarily resulted from a significant increase in Research and Development (R&D) expenses, which reached $150 million (up from $120 million in 2024). The company aggressively invested these funds into its internal drug pipeline and platform enhancements.

Management Discussion (MD&A Highlights): Key Achievements and Operational Highlights:

• Software Platform Advancement: Schrodinger launched major updates to its flagship software, adding enhanced AI/ML capabilities and new modules for specific therapeutic areas. This boosted enterprise customer adoption by 10%.
• Internal Pipeline Progress: The company successfully moved two oncology programs into pre-clinical studies (required before human trials), with applications to begin human trials (IND filings) expected in late 2026. It also initiated a Phase 1 clinical trial for its lead immunology candidate, SDGR-101, in Q3 2025.
• Strategic Collaborations: Schrodinger signed two new multi-year drug discovery partnerships with major pharmaceutical companies. These agreements could potentially generate up to $500 million in future milestone payments and royalties per agreement, in addition to upfront payments received in 2025.
• Intellectual Property: The company strengthened its patent portfolio, securing 25 new patents globally. These patents cover both its software technology and novel drug compounds.

Financial Health: Schrodinger ended 2025 with a strong cash position, holding $450 million in cash and marketable securities. This provides ample financial flexibility and runway for continued R&D investment.

Future Outlook: Schrodinger's strategy centers on two core pillars:

1. Expanding Software Leadership: The company plans to continuously innovate its platform, attracting new customers and deepening existing relationships. It aims for double-digit software revenue growth in 2026.
2. Advancing Drug Pipeline: Schrodinger will aggressively move its internal drug candidates through preclinical and clinical development. Its goal is to file 2-3 new applications to begin human trials (INDs) in the next fiscal year. The company also plans to selectively pursue new strategic collaborations to leverage its platform and share development risks.

Competitive Position: Schrodinger operates in highly competitive markets for both its computational software platform and its internal drug discovery efforts. Its competitive advantages include its proprietary physics-based modeling and machine learning platform, which offers advanced capabilities for accurate prediction and optimization. The company's integrated approach—combining a leading software platform with an internal drug pipeline—continuously validates and improves its technology, creating a powerful competitive advantage. A robust intellectual property portfolio also protects its core technologies and drug candidates. Key competitors include other computational chemistry software providers, contract research organizations (CROs) offering computational services, and traditional pharmaceutical and biotech companies with internal drug discovery capabilities. Schrodinger differentiates itself through the depth and breadth of its platform's predictive power and its ability to apply this technology to accelerate drug discovery across multiple therapeutic areas.

Risk Factors: Investors should be aware of several critical risks:

• Clinical Trial Success: The success of Schrodinger's drug candidates is highly uncertain, requiring rigorous clinical trials and regulatory approval. Failure at any stage could significantly impact future revenue and profits.
• Intense Competition: The drug discovery and software markets are highly competitive, demanding continuous innovation to maintain market share.
• Reliance on Collaborations: A significant portion of the company's drug discovery revenue depends on successful partnerships and milestone achievements, which are not guaranteed.
• High R&D Expenses: Schrodinger's continued investment in R&D means it may remain unprofitable for the foreseeable future, demanding careful cash management.
• Intellectual Property Protection: The ability to protect its proprietary software and drug candidates is crucial for long-term success.

In summary, Schrodinger, Inc. achieved solid software revenue growth and advanced its drug pipeline in 2025. This progress, however, came with increased net losses due to heavy R&D investment. While its strong cash position and strategic partnerships provide a foundation for future growth, investors must carefully consider the inherent risks of drug development and competitive pressures.